The FY2025 (Dec) proxy of Arcutis Biotherapeutics names 17 peer companies for pay. Among Arcutis Biotherapeutics and these peers, CEO pay was 5th highest of 7 and total shareholder return was 5th highest of 7.
5th highest of 7in Arcutis Biotherapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$5.4M$12.9M
5th highest of 7in Arcutis Biotherapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$63$495
Pay peer group, FY2025 (Dec) proxy
| Protagonist Therapeutics | ||
| Mirum Pharmaceuticals | ||
| Travere Therapeutics | ||
| Ardelyx | ||
| Tarsus Pharmaceuticals | ||
| Agios Pharmaceuticals | ||
| AnaptysBio | Not disclosed | Not disclosed |
| Biocryst Pharmaceuticals | Not disclosed | Not disclosed |
| Dynavax Technologies | Not disclosed | Not disclosed |
| Evolus | Not disclosed | Not disclosed |
| Mannkind | Not disclosed | Not disclosed |
| Ocular Therapeutics | Not disclosed | Not disclosed |
| Phathom Pharmaceuticals | Not disclosed | Not disclosed |
| Sage Therapeutics | Not disclosed | Not disclosed |
| Vanda Pharmaceuticals | Not disclosed | Not disclosed |
| Vericel | Not disclosed | Not disclosed |
| Y-mAbs Therapeutics | Not disclosed | Not disclosed |
17 companies
Changes by year
FY2025 (Dec) proxy
- AddedArdelyxpay peer group
- AddedDynavax Technologiespay peer group
- AddedEvoluspay peer group
- AddedMirum Pharmaceuticalspay peer group
- AddedOcular Therapeuticspay peer group
- AddedPhathom Pharmaceuticalspay peer group
- AddedVericelpay peer group
- RemovedAlectorpay peer groupbecause their clinical program was in an earlier stage of development
- RemovedBluebird Biopay peer groupbecause their market capitalizations were no longer in our targeted range
- RemovedCara Therapeuticspay peer groupbecause their market capitalizations were no longer in our targeted range
- RemovedCoherus Oncologypay peer groupbecause their market capitalizations were no longer in our targeted range
- RemovedSeres Therapeuticspay peer groupbecause their market capitalizations were no longer in our targeted range
FY2024 (Dec) proxy
- AddedBluebird Biopay peer group
- AddedCoherus Biosciencespay peer group
- AddedProtagonistpay peer group
- AddedSerespay peer group
- AddedTarsuspay peer group
- RemovedAxsome Therapeuticspay peer groupbecause their market capitalizations were no longer in our targeted range
- RemovedBridgeBio Pharmapay peer groupbecause their market capitalizations were no longer in our targeted range
- RemovedFibroGenpay peer groupdue to their recent clinical challenges at the time the peer group was reviewed
- RemovedKaruna Therapeuticspay peer groupbecause their market capitalizations were no longer in our targeted range
- RemovedKura Oncologypay peer groupbecause their clinical program was in an earlier stage of development
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.